CMF in its range of schedules is often considered a standard regimen for first line treatment of metastatic breast cancer with response rates between 30 to 60%.
Bishop et alr carried out a comparison of CMFP every 4 weeks (cyclophosphamide, methotrexate, fluorouracil and prednisone) with paclitaxel 200 mg/m2 every 3 weeks for 8 cycles.
Initial paclitaxel was associated with less myelosuppression and fewer infections, with longer survival and similar quality of life and control of metastatic breast cancer compared with CMFP.
A randomized trial, carried out by the ANZ Breast Cancer Trials Group, compared CMFP every 4 weeks with single agent mitozantrone (MTZ) as first line chemotherapy in women with metastatic breast cancer. CMFP resulted in a higher response rate than MTZ (39% vs 24%, p=0.002), and time to progressive disease (5.7 months vs 4.4 months, p=0.02), but was associated with greater toxicity (including mucositis, diarrhoea and infection).r
Median survival duration of 13.9 months for previously untreated patients with metastatic breast cancer.r
Progression-free survival r
© Journal of Clinical Oncology 1999
|Adverse events r
||All grades (%)
||Grade 3/4 (%)
|Fever without infection